Patent ID: 8933023
Filing Date: 2015-01-13
Classification: A61K,A61P

Abstract:
1. An injectable insulin composition comprising an active agent and an effective amount of a dissolution agent and a zinc chelator to dissociate and charge mask the insulin to enhance uptake and transport of the insulin through epithelial cells as compared to insulin in combination with a zinc chelator and HCl, wherein the active agent consists of insulin hexamers dissociated by the zinc chelator, wherein the dissolution agent is selected from the group consisting of glutamic, succinic, aspartic, maleic, fumaric, and adipic acid, and wherein the zinc chelator is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), ethylene-bis(oxyethylene nitro) tetraacetic acid (EGTA), dimercaptosuccinic acid (DMSA), and CDTA (1,2-diaminocyclohexanetetraacetic acid), alone or in combination with ions of a metal.